Effects and safety of pacilitaxelin association with gemcitabine in treating advanced non-small-cell lung cancer in the elderly

VernacularTitle:吉西他滨联合紫杉醇治疗老年晚期非小细胞肺癌的疗效与安全性
Author: Qing-Feng FANG ¹ ; Jin-Feng WANG
Author Information

1. 衙州市人民医院
Keywords: advanced non-small-cell lung cancer; gemcitabine; paclitaxel
From: The Chinese Journal of Clinical Pharmacology 2010;26(1):7-8,15
CountryChina
Language:Chinese
Abstract: Objective To evaluate the safety and curative effect of pacili-taxelin association with gemcitabine in treating advanced non-small-cell lung cancer(NSCLC)in the elderly.Methods From may 2002 to april 2008,35 patients were treated with this way,and 33 patients have com-plished 3 period of chemotherapy.Their clinical data Was retrospectively reviewed and analyzed.Results The overall response rate was 51.51%,including 2 case of cure(6.06%),15 cases of marked im-provement(45.45%),9 cases of failure(27.27%).The median sur-vial time was 10 months,the median progression time was 8 months,1 year survival rates were 45.16%.The adverce drug reaction(ADR)in-cluded bone marrow depression,liver function damage,alopecia,mucositis and peripheral neurotoxicity.Conclusion Pacilitaxelin association with gemcitabine has a better therapeutic effect in treating advanced NSCLC in the elderly.The ADR is slight.